RED BANK, N.J., March 3, 2022 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced that management will participate in two upcoming virtual
investor conferences in March.
Ashleigh Palmer, Provention Bio's
Chief Executive Officer and Co-Founder will participate in a
company presentation at the Cowen 42nd Annual Health
Care Conference on Tuesday, March 8th,
2022, at 9:50 am EST. The
presentation will be webcast live and can be accessed by visiting
the Events and Webcasts section of the Company's website:
http://investors.proventionbio.com/events.
Additionally, the company announced management will participate
in a fireside chat presentation at the Oppenheimer & Co. 32nd
Annual Healthcare Conference on Wednesday,
March 16th, 2022, at 2:00
pm EST. The fireside chat will be webcast live and can be
accessed by visiting the Events and Webcasts section of the
Company's website: http://investors.proventionbio.com/events.
Both webcasts will be archived on the Company's website for 30
days following the presentation.
About Provention Bio, Inc.:
Provention Bio, Inc.
(Nasdaq: PRVB) is a biopharmaceutical company focused on advancing
the development of investigational therapies that may intercept and
prevent debilitating and life-threatening immune-mediated disease.
The Company's pipeline includes clinical-stage product candidates
that have demonstrated in pre-clinical or clinical studies
proof-of-mechanism and/or proof-of-concept in autoimmune diseases,
including type 1 diabetes, celiac disease and lupus. Visit
www.ProventionBio.com for more information and follow us on
Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc.
uses its website, www.proventionbio.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation F.D. Such disclosures
will be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contacts:
Robert
Doody
VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-two-upcoming-virtual-investor-conferences-301494231.html
SOURCE Provention Bio, Inc.